PhoreMost
@PhoreMostLtd
Followers
646
Following
55
Media
412
Statuses
533
PhoreMost is a new-model drug discovery company dedicated to ‘Drugging the Undruggable®’ PhoreAll and PhoreEST are our dedicated inclusion & green initiatives.
Cambridge, England
Joined January 2017
📢 A rational approach to molecular glue discovery: GlueSEEKER™. Molecular glues are an emerging class of drug that exploit the cell’s proteostasis mechanisms by inducing close proximity between a target protein and an effector protein, like an E3 ligase, gluing them together.
1
2
1
We’re pleased to welcome Dr Adam Gilbert to our Scientific Advisory Board, supporting the progression of our novel small molecule degraders and molecular glues arising from our GlueSEEKER® platform. Read more:
0
1
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
721
3K
10K
📣 Published data validates GlueSEEKER®! Building on our expertise in mini-protein engineering and high-throughput screening, our latest manuscript marks a key milestone for GlueSEEKER, validating its potential to accelerate the development of MGDs ➡️
0
1
1
Exciting announcement! We’ve welcomed Barbara Duncan as Chair and Stephen Dilly as Non-Executive Director to our Board, bringing commercial and leadership expertise to advance our degrader pipeline and the commercialisation of our GlueSEEKER® platform. ➡️
0
0
0
🎄 Happy Holidays from PhoreMost 🎄. A big thank you to our team and all our partners for making this year a great one. We’re looking forward to the new year ahead!. Merry Christmas and Happy New Year!
0
0
1
Two months after @ELRIG_UK Drug Discovery, it’s great to see the conversations and insights continuing!. Check out our poster “Uncovering New Pathways for Targeted Protein Degradation" on @NewsMedical: . #TPD #DegraderTherapeutics
0
1
3
We had a fantastic evening at Scrip Awards earlier this week!. We’re honoured to be shortlisted for the MSD Innovation Award for the 2nd year running, a testament to the potential of our SITESEEKER and GlueSEEKER platforms to unlock new medicines. Congratulations to the winners!
0
0
1
📢We are recruiting a dedicated and enthusiastic Lab Technician to join our team!. Responsibilities include:.🧪 General lab maintenance and housekeeping.🧪 Maintaining lab stocks.🧪 Waste management. Find out more and apply here: #Cambridgejobs #Biotech
0
0
0
#DDCEurope is in full swing!. Earlier, Alberto Moreno De La Gandara shared updates on our GlueSEEKER platform in his talk, “Molecular Glue Discovery by High-throughput Neomorphic Remodelling of Effector Proteins”. To learn more, visit ➡️
0
0
0
📢A rational approach to molecular glue discovery: GlueSEEKER™.Molecular glues are an exciting class of protein degrader drugs - smaller, simpler than bivalents - but have so far been discovered by serendipity. To address this, we developed GlueSEEKER➡️
0
0
0
Next week, we’re off to Barcelona for #DDCEurope!. Catch Alberto Moreno De La Gandara, Associate Director for Target Biology, on Day 1 for his talk on #MolecularGlue discovery. For the full agenda, visit ➡️
0
0
0
Have you read our Meet the Team blog series?. In the latest edition, we spoke with Dr Jia Lu, Principal Scientist in Target Discovery about his experiences working with mini proteins and the challenges associated with developing molecular glue degraders➡️
0
0
0
Dr Benedict Cross spoke with @medicine_maker, sharing his insights into innovations in molecular glues and how they can improve therapeutic outcomes by drugging the undruggable. 📰 If you haven’t already, read the full article here:
0
1
2
Our team is in London for the 15th edition of #MedicineAtTheCrick!. Hosted by @TheCrick, today’s symposium explores new frontiers in drug discovery. Get in touch ➡️
0
0
1
Founded as a spinout from @Cambridge_Uni and supported by its innovation arm @UCamEnterprise, we are pioneering new technologies to identify druggable targets. Read this case study to learn more about our story:
0
0
0
Our team is back from a busy week at #BIOEurope!. Didn’t manage to schedule a meeting with us in person? Get in touch during the online digital partnering event to learn more about how we’re enabling the discovery of novel degrader therapeutics: info@phoremost.com
0
0
0
We had a great time at the TPD and Induced Proximity Summit, hearing about recent advances in MGDs, degrader therapeutics, and novel TPD mechanisms, as well as sharing updates on our internal pipelines. Missed our presentations? Contact us to learn more:.
0
0
0
Dr Neil Torbett and Dr Ian Hutchison are at #BIOEurope, meeting with leaders from life sciences to discuss the latest opportunities for collaborative innovation. Interested in learning how we are enabling discovery of degrader therapeutics? Get in touch: info@phoremost.com
0
0
0
“The next decade promises further innovation in the rational design of molecular glues”. In a recent article with @Medicine_maker, Dr Ben Cross explored how innovations in MGDs will overcome limitations of other degraders, improving therapeutic outcomes. 📰
0
1
1
Our team has arrived in Boston for the TPD and Induced Proximity Summit!.🎤 Visions for the future of TPD and Beyond - 29/10 8:15.🎤 CEO Think Tank - 29/10 9:30.🎤 Discovery of Bifunctional Degraders - 30/10 11:30.🎤 A Systematic Platform to Unlock MGDs - 31/10 13:30
0
0
0
💡 A brilliant idea for helping cancer patients is just an idea until it's put into practice. Here, @Cambridge_Uni explores 10 of its spinouts #ChangingTheStoryOfCancer, including PhoreMost, by developing more effective and targeted oncology therapies:
0
0
2